Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 41 to 50 of 86

Keyword or reference number: cancer`Remove $Keyword or reference number: cancer filter`

Guidance and quality standards awaiting development
Title	Type
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]	Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer [TSID10690]	Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]	Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer [ID6613]	Technology appraisal guidance
Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399]	Technology appraisal guidance
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]	Technology appraisal guidance
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [TSID11808]	Technology appraisal guidance
Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]	Technology appraisal guidance
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]	Technology appraisal guidance
Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer [TSID11810]	Technology appraisal guidance

Results per page

10
25
50
All